MARKET

TLSA

TLSA

TIZIANA LIFE SCIENCES PLC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.650
-0.163
-5.80%
Opening 09:33 11/21 EST
OPEN
2.660
PREV CLOSE
2.813
HIGH
2.660
LOW
2.650
VOLUME
566
TURNOVER
--
52 WEEK HIGH
6.09
52 WEEK LOW
1.670
MARKET CAP
36.85M
P/E (TTM)
-9.1982
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TLSA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

TLSA News

  • Barron's Picks And Pans: Medtronic, Tesla, Walmart And More
  • Benzinga.3d ago
  • The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout
  • Benzinga.10/11 12:14
  • Tiziana Life Sciences Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers
  • Business Wire.09/16 12:44
  • Tiziana Life Sciences Reports FDA Approval To Initiate Phase 1 Trial Of Foralumab In Healthy Volunteers
  • Benzinga.09/16 11:45

More

Industry

Biotechnology & Medical Research
-0.10%
Pharmaceuticals & Medical Research
-0.19%

Hot Stocks

Name
Price
%Change

About TLSA

Tiziana Life Sciences PLC is a clinical-stage biotechnology company. The Company is focused on targeted drugs to treat diseases in oncology and immunology, with a focus on metastatic cancers. Its lead product candidates include Milciclib (TZLS-201) and Foralumab (TZLS-401). Its products also include Anti IK-6r (TZLS-501) and StemPrintER. The Company is focused on its lead compound, Milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (CDK) involved in cell division, as well as a number of other protein kinases. Milciclib has completed Phase IIa trials as a monotherapy for the treatment for thymic carcinoma and hepatocellular carcinoma (HCC). The Company's Foralumab is a fully human engineered anti-human cluster of differentiation 3 (CD3) antibody. Foralumab has completed Phase II trial and has potential application in a wide range of autoimmune and inflammatory diseases.
More

Webull offers Tiziana Life Sciences PLC (TLSA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.